Adenocarcinoma in Situ disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ADN012 MIFTS: 43	Adenocarcinoma in Situ Categories: Cancer diseases, Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Adenocarcinoma in Situ

MalaCards integrated aliases for Adenocarcinoma in Situ:

Name: Adenocarcinoma in Situ ¹² ⁴⁴ ¹⁵ ⁷²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Endocrine diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4943

MeSH ⁴⁴ D065311

NCIt ⁵⁰ C4123

SNOMED-CT ⁶⁸ 51642000

UMLS ⁷² C0334276

Sources

Summaries for Adenocarcinoma in Situ

Disease Ontology : ¹² An in situ carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Adenocarcinoma in Situ is related to suppressor of tumorigenicity 3 and appendix adenocarcinoma. An important gene associated with Adenocarcinoma in Situ is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Vaccines and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include lung, cervix and testes, and related phenotypes are Reduced mammosphere formation and cellular

Sources

Related Diseases for Adenocarcinoma in Situ

Diseases in the Adenocarcinoma family:

Adenocarcinoma in Situ

Diseases related to Adenocarcinoma in Situ via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)

#	Related Disease	Score	Top Affiliating Genes
1	suppressor of tumorigenicity 3	30.5	CDKN2A CDKN1A
2	appendix adenocarcinoma	30.5	KRT7 KRT20 CDX2
3	endometrial adenocarcinoma	30.4	KRT7 KRAS CDKN2A
4	cervical adenocarcinoma	30.3	KRT7 KRT20 CDX2 CDKN2A CDKN1A
5	bronchiolo-alveolar adenocarcinoma	30.3	KRT7 KRT20 KRAS CDX2
6	endometrial mucinous adenocarcinoma	30.3	PAX2 CDKN2A
7	peritoneum cancer	30.3	PAX8 KRT7
8	duodenum adenocarcinoma	30.2	KRT7 KRAS CDX2
9	dermoid cyst	30.2	KRT7 KRT20
10	villous adenoma	30.0	KRT20 KRAS CDX2
11	glandular cystitis	30.0	KRT7 KRT20 CDX2
12	ovarian mucinous neoplasm	30.0	KRT7 KRT20 CDX2
13	cystic teratoma	30.0	KRT7 KRT20 CDX2
14	transitional cell carcinoma	30.0	KRT7 KRT20 CDKN2A
15	papillary carcinoma	29.9	PAX8 KRT7 KRT20
16	colorectal adenocarcinoma	29.9	KRT7 KRT20 KRAS CDX2
17	mucinous adenocarcinoma	29.8	KRT7 KRT20 KRAS CDX2 CDKN2A
18	mammary paget's disease	29.8	KRT7 KRT20
19	endocervical adenocarcinoma	29.7	PAX8 PAX2 KRT7 KRT20 CDX2 CDKN2A
20	pseudomyxoma peritonei	29.7	KRT7 KRT20 KRAS CDX2
21	intrahepatic cholangiocarcinoma	29.6	KRT7 KRT20 KRAS CDX2
22	colon adenocarcinoma	29.6	KRT20 KRAS CDKN1A
23	papilloma	29.4	KRT7 KRT20 CDKN2A CDKN1A
24	large cell neuroendocrine carcinoma	29.3	KRT7 KRT20
25	barrett esophagus	29.3	MCM2 KRT7 KRT20 CDX2 CDKN2A
26	lung cancer susceptibility 3	28.4	KRT7 KRT20 KRAS H19 CDX2 CDKN2A
27	endometrial cancer	28.4	PAX8 KRT7 KRAS H19 CDKN2A CDKN1A
28	cholangiocarcinoma	28.1	KRT7 KRT20 KRAS H19 CDX2 CDKN2A
29	lung cancer	27.8	KRT7 KRT20 KRAS H19 CDKN2A CDKN1A
30	in situ pulmonary adenocarcinoma	11.4
31	early invasive cervical adenocarcinoma	11.2
32	adenocarcinoma	10.9
33	inverted transitional papilloma	10.6	KRT7 CDKN2A
34	ovary neuroendocrine neoplasm	10.6	KRT7 CDX2
35	anus adenocarcinoma	10.6	KRT7 CDX2
36	mucinous adenofibroma	10.6	KRT7 CDX2
37	bladder carcinoma in situ	10.6	KRT7 CDKN2A
38	adenoid basal cell carcinoma	10.6	KRT7 CDKN2A
39	vulvar disease	10.6	KRT7 CDKN2A
40	cystic basal cell carcinoma	10.6	KRT7 KRT20
41	epithelial predominant wilms' tumor	10.6	KRT7 CDX2
42	anal canal carcinoma	10.6	KRT7 CDKN2A
43	renal pelvis adenocarcinoma	10.6	PAX8 KRT7
44	malignant syringoma	10.6	KRT7 KRT20
45	transverse colon cancer	10.6	KRT7 KRT20
46	alveoli adenoma	10.6	KRT7 KRAS
47	seminal vesicle adenocarcinoma	10.6	KRT7 KRT20
48	endosalpingiosis	10.6	PAX8 KRT7
49	sensory organ benign neoplasm	10.5	PAX8 KRT7
50	well-differentiated liposarcoma	10.5	KRT7 CDKN2A

Graphical network of the top 20 diseases related to Adenocarcinoma in Situ:

Sources

Symptoms & Phenotypes for Adenocarcinoma in Situ

GenomeRNAi Phenotypes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

²⁶

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Reduced mammosphere formation	GR00396-S	9.1	CLDN1 H19 KRAS KRT7 MCM2 PAX8

MGI Mouse Phenotypes related to Adenocarcinoma in Situ:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	9.97	CDKN1A CDKN2A CDX2 KRAS KRT7 MCM2
2	embryo	MP:0005380	9.87	CDKN1A CDKN2A CDX2 KRAS MCM2 PAX2
3	endocrine/exocrine gland	MP:0005379	9.8	CDKN1A CDKN2A CDX2 KRAS MCM2 PAX2
4	neoplasm	MP:0002006	9.55	CDKN1A CDKN2A CDX2 KRAS MCM2
5	pigmentation	MP:0001186	9.26	CDKN2A KRAS MCM2 PAX2
6	renal/urinary system	MP:0005367	9.1	CDKN1A CLDN10 KRAS KRT7 PAX2 PAX8

Sources

Drugs & Therapeutics for Adenocarcinoma in Situ

Drugs for Adenocarcinoma in Situ (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 31)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Vaccines

Phase 4

Immunologic Factors

Phase 4

Sargramostim

Approved, Investigational

Phase 1, Phase 2

83869-56-1, 123774-72-1

Cyclophosphamide

Approved, Investigational

Phase 1, Phase 2

50-18-0, 6055-19-2

2907

Testosterone

Approved, Experimental, Investigational

Phase 1, Phase 2

481-30-1, 58-22-0

6013 10204

nivolumab

Approved

Phase 2

946414-94-4

Ipilimumab

Approved

Phase 2

477202-00-9

Metformin

Approved

Phase 2

657-24-9

4091 14219

Hormone Antagonists

Phase 1, Phase 2

Alkylating Agents

Phase 1, Phase 2

Androgens

Phase 1, Phase 2

Hormones

Phase 1, Phase 2

Immunosuppressive Agents

Phase 1, Phase 2

Antirheumatic Agents

Phase 1, Phase 2

Antineoplastic Agents, Alkylating

Phase 1, Phase 2

Hormones, Hormone Substitutes, and Hormone Antagonists

Phase 1, Phase 2

Antibodies

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Immunoglobulins

Phase 2

Antibodies, Monoclonal

Phase 2

Hypoglycemic Agents

Phase 2

acetic acid

Approved

64-19-7

176

Proflavine

Approved

92-62-6

7099

Fenbendazole

Vet_approved

43210-67-9

3334

Hemostatics

Coagulants

Lugol's solution

Retinol acetate

127-47-9

10245972

Pharmaceutical Solutions

Anti-Infective Agents

Anti-Infective Agents, Local

Interventional clinical trials:

(show all 30)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase IV Open-Label, Descriptive Study to Evaluate the Safety and Effectiveness on the Incidence of HPV 6, 11, 16 and 18 Related CIN 2/3 or Worse of the Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in 16- to 26-Year-Old Japanese Women	Completed	NCT01544478	Phase 4
2	A Scientific Evaluation of One or Two Doses of Vaccine Against Human Papillomavirus: the ESCUDDO Study	Recruiting	NCT03180034	Phase 4
3	A Prospective Study of Ablation of Pulmonary Focal Pure Ground Glass Opacity	Unknown status	NCT01429649	Phase 3
4	A Phase III Open-label Safety and Immunogenicity Study of GARDASIL™9 Administered to 9- to 26-Year-Old Females and Males in Vietnam	Completed	NCT03546842	Phase 3
5	A Study to Evaluate the Efficacy of Quadrivalent HPV Vaccine in Reducing the Incidence of HPV 6-, 11-, 16-, and 18-Related CIN, AIS, and Cervical Cancer, and HPV 6-, 11-, 16-, and 18-Related External Genital Warts, Vulvar Intraepithelial Neoplasia Vaginal Intraepithelial Neoplasia, Vulvar Cancer, and Vaginal Cancer in 16- to 23-Year-Old Women	Completed	NCT00092521	Phase 3
6	A Randomized, Placebo-Controlled, Double-Blind Study of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine to Investigate the Safety, and Efficacy in Chinese 20 - to 45-Years-Old Women	Completed	NCT00834106	Phase 3
7	A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.	Completed	NCT00128661	Phase 3
8	A Phase 3 Randomized, Double-Blinded, Controlled With GARDASIL® Efficacy, Immunogenicity and Safety Study of V503 [a 9-Valent HPV Vaccine] in Chinese Women 20 to 45 Years of Age	Recruiting	NCT03998254	Phase 3	V503;Gardasil
9	A Phase 3 Open-Label Clinical Trial to Study the Immunogenicity, Safety and Tolerability of Recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, 18) Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years	Active, not recruiting	NCT03493542	Phase 3
10	Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion	Not yet recruiting	NCT02011997	Phase 3
11	A Neoadjuvant Immunologic Study of Androgen Deprivation Therapy Combined With a Granulocytemacrophage-colony Stimulating Factor F-secreting Allogeneic Prostate Cancer Vaccine and Low-dose Cyclophosphamide in Men With High-risk Localized Prostate Cancer Undergoing Radical Prostatectomy	Completed	NCT01696877	Phase 1, Phase 2	degarelix acetate;Cyclophosphamide;GVAX
12	DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	Recruiting	NCT02834013	Phase 2
13	Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer: An Internal Pilot Study	Active, not recruiting	NCT03053544	Phase 2	Metformin
14	Conservative Surgery for Women With Low-risk, Early Stage Cervical Cancer	Active, not recruiting	NCT01048853	Phase 2
15	Morphometric Diagnosis of Atypical Glandular Lesions Using a Conventional Pap Smear From GOG-0171 Patients (Enrolled by GOG-Japan) With a Cytologic Diagnosis of Atypical Glandular Cells of Unspecified Significance (AGUS)	Unknown status	NCT00898144
16	Prospective Cohort Study of Telomere Biology Among Patients With Early Adenocarcinoma of the Lung	Unknown status	NCT02239432
17	Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil)	Unknown status	NCT03195218
18	Point‐of‐Care, Real‐Time Optical Imaging to Enable Screening for Cervical Cancer and Its Precursors in Low‐Resource Settings	Completed	NCT02494310
19	Post Colposcopy Management of ASC-US and LSIL Pap Tests (PALS Trial): Pilot Study	Completed	NCT03466710
20	Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients With a Cytologic Diagnosis of Atypical Glandular Cells (AGC)	Recruiting	NCT00892866
21	A Prospective and Multi-center RCT Study of Lymphadenectomy Based on Intraoperative Frozen Pathology for Pulmonary Invasive Adenocarcinoma Presenting With Ground Glass Opacity	Recruiting	NCT03322826
22	Establishment and Evaluation for Pathological Diagnostic Criteria of Intraoperative Frozen Section of Early Stage Lung Cancer	Recruiting	NCT02941003
23	HSIL/ACIS/Early Cervical Cancer: What Are The Current Causative HPV Subtypes in the Era of HPV Vaccination?	Recruiting	NCT02937155
24	Prevalence of Anal Dysplasia and Anal Cancer in Women With Cervical, Vaginal and Vulvar Dysplasia and Cancer	Recruiting	NCT02140021
25	Use of High-Resolution Microendoscopy (HRME) in Patients With Adenocarcinoma In-Situ (AIS) of the Cervix	Active, not recruiting	NCT02206048		Proflavine
26	A Clinical Pathway for the Treatment of Multifocal Lung Adenocarcinoma Using Genome Sequencing	Active, not recruiting	NCT01946100
27	A Prospective, Multi-centre Post Marketing Surveillance (PMS) Cohort Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV)-16/18 L1 VLP AS04 Vaccine in Female Chinese Subjects Aged Between 9 and 45 Years, When Administered According to the Prescribing Information (PI) as Per Routine Practice.	Active, not recruiting	NCT03438006
28	A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome	Enrolling by invitation	NCT02705404
29	A Long-term Follow-up Registry-based Cohort Study of HPV Vaccine Efficacy Against Cervical Pre-cancerous Lesions and Cervical Cancers in a Cohort of Females Previously Enrolled From Finland in Study HPV-008, as Compared to a Non-intervention Population -Based Reference Cohort of Females From Finland	Enrolling by invitation	NCT01393470
30	Pilot Study of the Hand-held In Vivo Confocal Microscopy Probe for Detection of Cervical Intraepithelial Neoplasia	Suspended	NCT02574442

Search NIH Clinical Center for Adenocarcinoma in Situ

Cochrane evidence based reviews: adenocarcinoma in situ

Sources

Genetic Tests for Adenocarcinoma in Situ

Sources

Anatomical Context for Adenocarcinoma in Situ

MalaCards organs/tissues related to Adenocarcinoma in Situ:

⁴¹

Lung, Cervix, Testes, Colon, Lymph Node, Prostate, Pancreas

Sources

Publications for Adenocarcinoma in Situ

Articles related to Adenocarcinoma in Situ:

(show top 50) (show all 1226)

#	Title	Authors	PMID	Year
1	Increased HPV detection by the use of a pre-heating step on vaginal self-samples analysed by Aptima HPV assay. ³⁸	Borgfeldt C...Forslund O	31002831	2019
2	Endocervical adenocarcinoma in situ (AIS) with ovarian and pulmonary involvement: report of a case and review of the literature suggesting a "seed and soil hypothesis". ³⁸	Horn LC...Brambs CE	31309301	2019
3	Should pathologically non-invasive lung adenocarcinoma larger than 3 cm be classified as T1a? ³⁸	Inafuku K...Masuda M	31400323	2019
4	Can texture features improve the differentiation of infiltrative lung adenocarcinoma appearing as ground glass nodules in contrast-enhanced CT? ³⁸	Gao C...Xu M	31307637	2019
5	Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women. ³⁸	Sakamoto M...Tanaka Y	30879979	2019
6	Missed Opportunities for HPV Vaccination Among Vaccine-Eligible Women with High Grade Cervical Lesions. ³⁸	Russ SM...Niccolai LM	31248688	2019
7	Is one dose of human papillomavirus vaccine as effective as three?: A national cohort analysis. ³⁸	Brotherton JM...Saville M	31319173	2019
8	[Thoracoscopic Left Upper Division Segmentectomy for Multiple Ground-glass Nodules Using Preoperative Virtual-assisted Lung Mapping]. ³⁸	Shimizu Y...Tsuchida M	31296803	2019
9	Multi-region exome sequencing reveals genomic evolution from preneoplasia to lung adenocarcinoma. ³⁸	Hu X...Zhang J	31278276	2019
10	Can we predict histological outcome of distinctive cohorts of patients with glandular cell abnormalities on ThinPrep Papanicolaou testing based on human papillomavirus status, age, and associated squamous abnormalities? ³⁸	Harbhajanka A...Michael CW	31359607	2019
11	Cytological differences between invasive and noninvasive or minimally invasive lung adenocarcinomas diagnosed in Japanese patients using needle biopsy specimens of pulmonary lesions ≤3 cm in diameter. ³⁸	Matsubayashi J...Nagao T	30968597	2019
12	Computer-aided diagnosis of ground-glass opacity pulmonary nodules using radiomic features analysis. ³⁸	Gong J...Peng W	31167172	2019
13	Endocervical Adenocarcinoma In Situ Phenotype with Ovarian Metastasis. ³⁸	Kim HS...Lee JH	30599504	2019
14	The new 8th TNM staging system of lung cancer and its potential imaging interpretation pitfalls and limitations with CT image demonstrations. ³⁸	Feng SH...Yang ST	31295144	2019
15	Adenocarcinoma in situ of the uterine cervix: Clinical practice guidelines from the Italian society of colposcopy and cervical pathology (SICPCV). ³⁸	Ciavattini A...Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV)	31352128	2019
16	Detection of HPV RNA molecules in stratified mucin-producing intraepithelial lesion (SMILE) with concurrent cervical intraepithelial lesion: a case report. ³⁸	Fukui S...Ayabe T	31159808	2019
17	Efficacy of quadrivalent human papillomavirus vaccine against persistent infection and genital disease in Chinese women: A randomized, placebo-controlled trial with 78-month follow-up. ³⁸	Wei L...Saah AJ	30122646	2019
18	Is the positive predictive value of high-grade cytology in predicting high-grade cervical disease falling due to HPV vaccination? ³⁸	Sultana F...Brotherton JML	30536935	2019
19	Adenocarcinoma in situ in type I congenital pulmonary airway malformation. ³⁸	Santosham R...Jacob SS	31226882	2019
20	Value of TSCT Features for Differentiating Preinvasive and Minimally Invasive Adenocarcinoma From Invasive Adenocarcinoma Presenting as Subsolid Nodules Smaller Than 3 cm. ³⁸	Wang H...Ji J	31201034	2019
21	Application of deep learning (3-dimensional convolutional neural network) for the prediction of pathological invasiveness in lung adenocarcinoma: A preliminary study. ³⁸	Yanagawa M...Tomiyama N	31232960	2019
22	Lung Adenocarcinoma Invasiveness Risk in Pure Ground-Glass Opacity Lung Nodules Smaller than 2 cm. ³⁸	Lee GD...Lee S	29359309	2019
23	Role of ThinPrep liquid-based cytology in evaluation of the endocervical canal in patients with abnormal cervical screening. ³⁸	Al-Nourhji O...Abdul-Karim FW	31186178	2019
24	Problems in the reproducibility of classification of small lung adenocarcinoma: an international interobserver study. ³⁸	Shih AR...Mino-Kenudson M	31107973	2019
25	Clinicopathological Characteristics of Atypical Glandular Cells Determined by Cervical Cytology in Japan: Survey of Gynecologic Oncology Data from the Obstetrical Gynecological Society of Kinki District, Japan. ³⁸	Toyoda S...Kobayashi H	31048578	2019
26	Clinical analysis of percutaneous computed tomography-guided injection of cyanoacrylate for localization of 115 small pulmonary lesions in 113 asymptomatic patients. ³⁸	Huang BY...Li L	30966824	2019
27	Challenges in the Pap diagnosis of endocervical adenocarcinoma in situ. ³⁸	Niu S...Lucas E	31097290	2019
28	The Incidence and Clinical Significance of Atypical Glandular Cells of Undetermined Significance on Cervical Pap Smears. ³⁸	Al-Rayyan E...Haddadin W	31242982	2019
29	Expression of Markers of Müllerian Clear Cell Carcinoma in Primary Cervical and Vaginal Gastric-type Adenocarcinomas. ³⁸	Talia KL...McCluggage WG	29901522	2019
30	CT-guided Microcoil Pulmonary Nodule Localization prior to Video-assisted Thoracoscopic Surgery: Diagnostic Utility and Recurrence-Free Survival. ³⁸	Rodrigues JCL...Nguyen ET	30720402	2019
31	Evaluation of Folate Receptor-Mediated Cervical Dyeing as a Method for Detection of Cervical Lesions. ³⁸	Zhao Y...Wei L	30817686	2019
32	Estimated Number of Cases of High-Grade Cervical Lesions Diagnosed Among Women - United States, 2008 and 2016. ³⁸	McClung NM...HPV-IMPACT Working Group	30998672	2019
33	Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015. ³⁸	Cleveland AA...HPV-IMPACT Working Group	30980692	2019
34	Histogram analysis combined with morphological characteristics to discriminate adenocarcinoma in situ or minimally invasive adenocarcinoma from invasive adenocarcinoma appearing as pure ground-glass nodule. ³⁸	Zhang T...Yu TF	30927953	2019
35	A comparison between 2- and 3-dimensional approaches to solid component measurement as radiological criteria for sublobar resection in lung adenocarcinoma ≤ 2 cm in size. ³⁸	Yoshida Y...Nakajima J	30968225	2019
36	RANZCOG Fellows' adherence to guidelines following cytological prediction of cervical adenocarcinoma-in-situ: Cause for concern? ³⁸	Powell A...Blomfield P	30284744	2019
37	Histogram-based models on non-thin section chest CT predict invasiveness of primary lung adenocarcinoma subsolid nodules. ³⁸	Oikonomou A...Nguyen ET	30979926	2019
38	Trends in High-grade Cervical Lesions and Cervical Cancer Screening in 5 States, 2008-2015. ³⁸	Gargano JW...HPV-IMPACT Working Group	30137283	2019
39	Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting. ³⁸	Landy R...Castle PE	30861114	2019
40	Distinctive clinicopathological features of adenocarcinoma in situ and minimally invasive adenocarcinoma of the lung: A retrospective study. ³⁸	Ishida H...Kobayashi K	30797486	2019
41	Histopathology of Women with “Atypical Squamous Cells Cannot Exclude High-Grade Squamous Intraepithelial Lesion” (ASC-H) Smears ³⁸	Ratree S...Luanratanakorn S	30909664	2019
42	A case study of gastric-type adenocarcinoma in situ of the uterine cervix. ³⁸	Tay A...Yeo YC	30417947	2019
43	Cervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix ³⁸	Srisomboon S...Srisomboon J	30803195	2019
44	Smear cytological features of large cell neuroendocrine carcinoma of the uterine cervix in pregnancy: A case report and review of the literature. ³⁸	Erdem BE...Izzet Y	30461217	2019
45	PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. ³⁸	Miyazawa T...Nakamura H	30282880	2019
46	Recent increase in incidence of cervical precancerous lesions in Norway: Nationwide study from 1992 to 2016. ³⁸	Orumaa M...Nygard M	30734284	2019
47	An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening. ³⁸	Hu L...Schiffman M	30629194	2019
48	Expressions of ATF6, XBP1, and GRP78 in normal tissue, atypical adenomatous hyperplasia, and adenocarcinoma of the lung. ³⁸	Ogata S...Nakanishi K	30121368	2019
49	Utility of imaging modalities for predicting carcinogenesis in lobular endocervical glandular hyperplasia. ³⁸	Omori M...Hirata S	31415639	2019
50	Three-dimensional navigation-guided thoracoscopic combined subsegmentectomy for intersegmental pulmonary nodules. ³⁸	Wu WB...Chen L	30390378	2019

Sources

Genes for Adenocarcinoma in Situ

Genes related to Adenocarcinoma in Situ (0 elite genes):

(show all 12)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	22.52	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
2	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	21.66	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
3	KRT7	Keratin 7	Protein Coding	21.5	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
4	CDX2	Caudal Type Homeobox 2	Protein Coding	20.32	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
5	PAX8	Paired Box 8	Protein Coding	20.17	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
6	KRT20	Keratin 20	Protein Coding	19.96	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
7	PAX2	Paired Box 2	Protein Coding	19.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
8	CLDN1	Claudin 1	Protein Coding	19.46	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
9	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	16.26	GeneCards inferred via : Publications (show sections)
10	CLDN10	Claudin 10	Protein Coding	16.26	GeneCards inferred via : Publications (show sections)
11	H19	H19 Imprinted Maternally Expressed Transcript	RNA Gene	16.26	GeneCards inferred via : Publications (show sections)
12	MCM2	Minichromosome Maintenance Complex Component 2	Protein Coding	16.26	GeneCards inferred via : Publications (show sections)

Sources

Variations for Adenocarcinoma in Situ

Sources

Expression for Adenocarcinoma in Situ

Search GEO for disease gene expression data for Adenocarcinoma in Situ.

Sources

Pathways for Adenocarcinoma in Situ

Pathways related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 11)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁷ Show member pathways Acute myeloid leukemia ³⁷ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁶ Chronic myeloid leukemia ³⁷ Colorectal cancer ³⁷ Pancreatic cancer ³⁷ Prostate cancer ³⁷ Signal transduction PTEN pathway ²² Thyroid cancer ³⁷	12.52	PAX8 KRAS CDKN2A CDKN1A
2	Pathways in cancer ³⁷	12.48	PAX8 KRAS CDKN2A CDKN1A
3	Gastric cancer ³⁷ Show member pathways Breast cancer ³⁷ Hepatocellular carcinoma ³⁷	12.34	KRAS CDX2 CDKN2A CDKN1A
4	Viral carcinogenesis ³⁷	11.97	KRAS CDKN2A CDKN1A
5	Cellular senescence (KEGG) ³⁷	11.81	KRAS CDKN2A CDKN1A
6	DNA Damage Response (only ATM dependent) ¹	11.49	KRAS CDKN2A CDKN1A
7	Glioblastoma Multiforme ⁶⁴	11.38	KRAS CDKN2A CDKN1A
8	Primary Focal Segmental Glomerulosclerosis FSGS ¹	11	PAX2 CLDN1 CDKN1A
9	TP53 Network ¹ Show member pathways Activation, translocation and oligomerization of BAX ⁶⁶	10.75	CDKN2A CDKN1A
10	Bladder cancer ³⁷ ¹	10.66	KRAS CDKN2A CDKN1A
11	ID signaling pathway ¹	10.53	PAX8 PAX2

Sources

GO Terms for Adenocarcinoma in Situ

Biological processes related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

(show all 25)

#	Name	GO ID	Score	Top Affiliating Genes
1	G1/S transition of mitotic cell cycle	GO:0000082	9.72	MCM2 CDKN2A CDKN1A
2	Ras protein signal transduction	GO:0007265	9.7	KRAS CDKN2A CDKN1A
3	cochlea development	GO:0090102	9.62	PAX2 MCM2
4	negative regulation of cyclin-dependent protein serine/threonine kinase activity	GO:0045736	9.62	CDKN2A CDKN1A
5	cellular senescence	GO:0090398	9.61	CDKN2A CDKN1A
6	calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules	GO:0016338	9.61	CLDN10 CLDN1
7	positive regulation of branching involved in ureteric bud morphogenesis	GO:0090190	9.6	PAX8 PAX2
8	positive regulation of cellular senescence	GO:2000774	9.59	KRAS CDKN2A
9	negative regulation of phosphorylation	GO:0042326	9.58	CDKN2A CDKN1A
10	urogenital system development	GO:0001655	9.58	PAX8 PAX2
11	replicative senescence	GO:0090399	9.57	CDKN2A CDKN1A
12	mesonephros development	GO:0001823	9.56	PAX8 PAX2
13	mesenchymal to epithelial transition involved in metanephros morphogenesis	GO:0003337	9.54	PAX8 PAX2
14	regulation of metanephric nephron tubule epithelial cell differentiation	GO:0072307	9.51	PAX8 PAX2
15	pronephros development	GO:0048793	9.49	PAX8 PAX2
16	metanephric epithelium development	GO:0072207	9.48	PAX8 PAX2
17	positive regulation of mesenchymal to epithelial transition involved in metanephros morphogenesis	GO:0072108	9.46	PAX8 PAX2
18	metanephric nephron tubule formation	GO:0072289	9.43	PAX8 PAX2
19	metanephric distal convoluted tubule development	GO:0072221	9.4	PAX8 PAX2
20	negative regulation of mesenchymal cell apoptotic process involved in metanephros development	GO:1900212	9.37	PAX8 PAX2
21	pronephric field specification	GO:0039003	9.32	PAX8 PAX2
22	positive regulation of metanephric DCT cell differentiation	GO:2000594	9.26	PAX8 PAX2
23	negative regulation of mesenchymal cell apoptotic process involved in metanephric nephron morphogenesis	GO:0072305	9.16	PAX8 PAX2
24	negative regulation of apoptotic process involved in metanephric nephron tubule development	GO:1900218	8.96	PAX8 PAX2
25	negative regulation of apoptotic process involved in metanephric collecting duct development	GO:1900215	8.62	PAX8 PAX2

Molecular functions related to Adenocarcinoma in Situ according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cyclin-dependent protein serine/threonine kinase inhibitor activity	GO:0004861	8.62	CDKN2A CDKN1A

Sources

Sources for Adenocarcinoma in Situ

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ TGDB

⁷¹ Tocris

⁷² UMLS

⁷³ UMLS via Orphanet

⁷⁴ UniProtKB/Swiss-Prot

⁷⁵ Wikipedia